FI67214B - Foerfarande foer framstaellning av nya terapeutiskt vaerdefulla taurinderivat - Google Patents

Foerfarande foer framstaellning av nya terapeutiskt vaerdefulla taurinderivat Download PDF

Info

Publication number
FI67214B
FI67214B FI821650A FI821650A FI67214B FI 67214 B FI67214 B FI 67214B FI 821650 A FI821650 A FI 821650A FI 821650 A FI821650 A FI 821650A FI 67214 B FI67214 B FI 67214B
Authority
FI
Finland
Prior art keywords
therapeutic
compounds
effect
taurine
added
Prior art date
Application number
FI821650A
Other languages
English (en)
Swedish (sv)
Other versions
FI821650L (fi
FI67214C (fi
FI821650A0 (fi
Inventor
Lars Henrik Andersen
Leif Albin Hilden
Original Assignee
Medica Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medica Pharma Co Ltd filed Critical Medica Pharma Co Ltd
Publication of FI821650L publication Critical patent/FI821650L/fi
Publication of FI821650A0 publication Critical patent/FI821650A0/fi
Publication of FI67214B publication Critical patent/FI67214B/fi
Application granted granted Critical
Publication of FI67214C publication Critical patent/FI67214C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (2)

1. Förfarande för framställning av nya terapeutiskt värdefulla taurinderivat enligt formel I | Nsn-ch2ch2so2nr1 ^ I där är H R2 är en metyl-, etyl-, n-propyl-, isopropyl e Her n-butylgrupp eller där /^| NR.^ ar N kännetecknat därav, att ftalimidoetansulfonyl-klorid enligt formel II I N-CH2CH2S02C1 II omsättes med en primär- eller sekundär amin med allmänna fontein NR^H, där , R2 och NR.^ har saimta betydelse som o van, i ett inert or-ganiskt lösningsmedel vid 0-50°C i närvaro av en bas, t.ex. i ett överskott av den ifrägavarande aminen enligt reaktionen III 15 6721 4 | NN-CH„CH„S0„C1 III I / 2 2 2 CO + HNR1R2 I | N-CHjCHjSOjNR,^ co7 eller därav, att ftalimidoetansulfonamid enligt forme1 IV I^Y“\ I N-CH2CH2S02NH2 IV tillates att reagera med alkyleringsmedel sasorn alkylhalogenider eller dlalkylsulfat i ett inert organiskt lösningsmedel genom att lata blandningen koka under aterlopp i närvaro av en bas, företrädesvis i närvaro av kaiiumkarbonat enligt reaktionen V Γ^ν°°\ N-CHoCHoS0oNHo V I j 2 2 2 2 v + »*2 /‘H2>2S04 ί^ιΓ'00'' . II / där X är en halogenid är väte R2 är en metyl-, etyl-, n-ptopy1-, isopropyl- eller n-butylgrupp 16 6721 4 Patenttivaatimus
1. Menetelmä uusien terapeuttisesti arvokkaiden kaavan I mukaisten tauriinijohdannaisten valmistamiseksi jossa R on H Rj on metyyli-, etyyli-, n-propyyli-, isopropyyli-tai n-butyyliryhma tai jossa —> NR^R2 o*"1 tunnettu siitä, että kaavan II mukaisen ftaali-imidoetaanisulfonyylikloridin I N-CH2CH2S0,C1 II annetaan reagoida primääri- tai sekundääriamiinin kanssa, jonka yleinen kaava on OTL,R^ missä , Rj ja NR^Rj merkitsevät samaa kuin yllä, inertisessä liuottimessa 0-50°C:ssa emäksen läsnäollessa esim. kyseessä olevan amiinin ylimäärässä reaktiokaavan III mukaan
FI821650A 1980-06-06 1982-05-11 Foerfarande foer framstaellning av nya terapeutiskt vaerdefulla taurinderivat FI67214C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE8004261A SE434638B (sv) 1980-06-06 1980-06-06 Nya terapeutiska verdefulla taurinderivat och deras framstellning
SE8004261 1980-06-06
PCT/FI1981/000037 WO1981003492A1 (en) 1980-06-06 1981-05-22 Chemical compounds,their production,and their use in drugs
FI8100037 1981-05-22

Publications (4)

Publication Number Publication Date
FI821650L FI821650L (fi) 1982-05-11
FI821650A0 FI821650A0 (fi) 1982-05-11
FI67214B true FI67214B (fi) 1984-10-31
FI67214C FI67214C (fi) 1985-02-11

Family

ID=20341162

Family Applications (1)

Application Number Title Priority Date Filing Date
FI821650A FI67214C (fi) 1980-06-06 1982-05-11 Foerfarande foer framstaellning av nya terapeutiskt vaerdefulla taurinderivat

Country Status (26)

Country Link
US (1) US4556673A (fi)
JP (1) JPS57500877A (fi)
AT (1) AT376206B (fi)
BE (1) BE889100A (fi)
CA (1) CA1165322A (fi)
CH (1) CH647505A5 (fi)
CS (2) CS235088B2 (fi)
DD (1) DD159427A5 (fi)
DE (1) DE3152071C2 (fi)
DK (1) DK155521B (fi)
ES (1) ES502761A0 (fi)
FI (1) FI67214C (fi)
FR (1) FR2486077B1 (fi)
GB (1) GB2093457B (fi)
HU (1) HU184871B (fi)
IE (1) IE51264B1 (fi)
IL (1) IL62824A (fi)
IT (1) IT8122151A0 (fi)
NL (1) NL8120217A (fi)
NO (1) NO155840C (fi)
PL (2) PL128574B1 (fi)
PT (1) PT73061B (fi)
SE (1) SE434638B (fi)
SU (1) SU1097198A3 (fi)
WO (1) WO1981003492A1 (fi)
ZA (1) ZA813387B (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007991A1 (en) * 1987-04-10 1988-10-20 Huhtamäki Oy Novel sulfonamides, a process for their preparation and pharmaceutical compositions containing these new sulfonamides

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
AR016384A1 (es) * 1997-07-30 2001-07-04 Smithkline Beecham Corp Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2006200033B8 (en) * 1998-10-30 2008-09-11 Celgene Corporation Substituted phenethylsulfones and methods of reducing TNF-alpha levels
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
WO2003000654A1 (en) * 2001-06-26 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Valproyltaurinamide derivatives as anticonvulsant and cns active agents
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
CN114539106B (zh) * 2022-03-15 2023-05-02 梯尔希(南京)药物研发有限公司 一种稳定同位素标记的牛磺酰胺盐酸盐的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2184279A (en) * 1937-11-27 1939-12-26 Squibb & Sons Inc Amino-aliphatic sulphonamides and process for preparing them
AT219039B (de) * 1959-05-27 1962-01-10 Geigy Ag J R Verfahren zur Herstellung von neuen Isoindolinderivaten
GB1254414A (en) * 1969-05-08 1971-11-24 Shun-Ichi Naito Novel aminoethanesulfonylamino derivatives and their production
US4093723A (en) * 1976-05-19 1978-06-06 Smithkline Corporation 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl) cephalosporins
ZA76757B (en) * 1975-03-18 1977-01-26 Smithkline Corp New cephalosporin compounds
US4048311A (en) * 1976-01-08 1977-09-13 Smithkline Corporation 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl)cephalosporins
US4066762A (en) * 1976-07-12 1978-01-03 Smithkline Corporation Derivatives of 7-(2-substituted-2-hydroxyiminoacetamido)-3-(1-substituted tetrazol-5-ylthiomethyl-3-cephem-4-carboxylic acid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007991A1 (en) * 1987-04-10 1988-10-20 Huhtamäki Oy Novel sulfonamides, a process for their preparation and pharmaceutical compositions containing these new sulfonamides

Also Published As

Publication number Publication date
DE3152071T1 (de) 1983-10-20
SE434638B (sv) 1984-08-06
ES8203342A1 (es) 1982-04-01
CS235088B2 (en) 1985-04-16
ZA813387B (en) 1982-06-30
NL8120217A (fi) 1982-08-02
WO1981003492A1 (en) 1981-12-10
FR2486077B1 (fi) 1988-08-12
DD159427A5 (de) 1983-03-09
IE51264B1 (en) 1986-11-26
NO155840C (no) 1987-06-10
PL128321B1 (en) 1984-01-31
SU1097198A3 (ru) 1984-06-07
FI821650L (fi) 1982-05-11
PT73061B (en) 1982-07-01
NO155840B (no) 1987-03-02
IL62824A (en) 1984-07-31
GB2093457B (en) 1984-03-21
CS235091B2 (en) 1985-04-16
US4556673A (en) 1985-12-03
HU184871B (en) 1984-10-29
SE8004261L (sv) 1981-12-07
IT8122151A0 (it) 1981-06-05
FR2486077A1 (fi) 1982-01-08
DK155521B (da) 1989-04-17
FI67214C (fi) 1985-02-11
DK30082A (da) 1982-01-25
CH647505A5 (de) 1985-01-31
PT73061A (en) 1981-06-01
IL62824A0 (en) 1981-07-31
CA1165322A (en) 1984-04-10
DE3152071C2 (de) 1989-06-15
BE889100A (fr) 1981-12-04
ES502761A0 (es) 1982-04-01
ATA907681A (de) 1984-03-15
IE811037L (en) 1981-12-06
GB2093457A (en) 1982-09-02
PL128574B1 (en) 1984-02-29
JPS57500877A (fi) 1982-05-20
PL235510A1 (fi) 1982-11-22
PL231531A1 (fi) 1982-08-30
FI821650A0 (fi) 1982-05-11
AT376206B (de) 1984-10-25
NO820213L (no) 1982-01-25

Similar Documents

Publication Publication Date Title
FI67214B (fi) Foerfarande foer framstaellning av nya terapeutiskt vaerdefulla taurinderivat
SI9111966A (sl) N-acil-2,3-benzodiazepinski derivati in postopek za njihovo pripravo
AU2001264116B2 (en) Amidine derivatives as selective antagonists of NMDA receptors
DE69927007T2 (de) Spisulosin-verbindungen mit antitumor-aktivität
US3261845A (en) N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
Werbel et al. Basically substituted ellipticine analogs as potential antitumor agents
Madsen et al. NMDA receptor agonists derived from ibotenic acid. Preparation, neuroexcitation and neurotoxicity
JP2580196B2 (ja) アミノ酸誘導体鎮痙薬
Angelova et al. Anticonvulsant activity of newly synthesized 2H-chromene based hydrazones in ICR mice
Wang et al. Synthesis and biological evaluation of peptidomimetics containing the tryptamine moiety as a potential antitumor agent
SE435927B (sv) Trans-4-(2-klorofenoxi)-1-etyl-pyrrolidinol med terapeutisk verkan
Blagbrough et al. Polyamine amide toxins as pharmacological tools and pharmaceutical agents
US8476258B2 (en) Compound having activity of blocking NMDA receptor channel, and pharmaceutical agent using the same
WO1996003122A2 (en) Use of gabapentin in the treatment of anxiety and panic
Leeson et al. Effects of five-membered ring conformation on bioreceptor recognition: identification of 3R-amino-1-hydroxy-4R-methylpyrrolidin-2-one (L-687,414) as a potent glycine/N-methyl-D-aspartate receptor antagonist
AU2014292860B2 (en) Vasopressin-2 receptor agonists
CN103709094B (zh) 4-苯氧基苯甲酰胺类化合物及其制备方法和应用
SE436203B (sv) Analogiforfarande for framstellning av 6-(substituerad fenyl)-2,4,7-triamino-pteridiner
EP2332529A1 (de) Substituierte aromatische Diamine als Liganden der vesikulären Glutamat-Transporter 1 und 2 (vGLUT1 und vGLUT2)
Spano et al. 1-Adamantanecarboxylic acid amide of 4-aminoantipyrine
CA3033497A1 (en) Modified peptides for use in treating neurodegenerative disorders
US3423412A (en) Benzopyrroloquinazolinones
WO2020160464A1 (en) Transient receptor potential melastatin 8 (trpm8) antagonists and related methods
Harutyunyan et al. Synthesis and conversions of polyhedral compounds. 28. Synthesis of 2-(naphthyl-1′) and 2-(2′-hydroxynaphthyl-1′) derivatives of 5, 7-dialkyl-1, 3-diazaadamantanes
JPH0229669B2 (fi)

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: LAEKEMEDELSFABRIKEN-MEDICA AB